Addressing the Challenges in Downstream Processing Today and Tomorrow - Newer classes of biotherapies will require innovations in processing technology. - BioPharm International

ADVERTISEMENT

Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.


BioPharm International Supplements
Volume 24, Issue 4, pp. s8-s15

29. D.P. Humphreys and L. Bowering, "Production of antibody Fab' fragments in E. coli." in Therapeutic Monoclonal Antibodies. Z. An, Ed. (John Wiley & Sons. Hoboken, NJ, 2009). pp 589–622.

30. R.E. Kontermann, Curr. Opin. Mol. Ther. 12 (2), 176–183 (2010).

31. C.E. Hagemeyer, et. al., Thromb Haemost. 101 (6) 1012-1019 (2009).

32. S.M. Kipriyanov., Methods Mol. Biol. 562, 205-214 (2009).

33. C.J. Fee. "Protein Conjugates Purification and characterization," in PEGylated Protein Drugs: Basic Science and Clinical Applications, F.M. Veronese, Ed. (Die Deutsche Bibliothek Berlin Germany, 2009.) pp. 113–125.

34. T.M. Pabst et. al., J. Chromatogr. A. 1147 (2), 172–182 (2007).

35. F.V. Bockstaele, J.B. Holz, and R. Hilde, Curr. Opin. Invest. Drugs 10 (11), 1212–1224 (2009).

36. P.R. Brown, S.A Tobler, A.M. Wood, and A.W. Boesch, US patent application, SU2010/0172894 A1 (2010).

37. E. Burova and E. Ioffe. Gene Ther. 12 (suppl. 1s), S6–S17 (2005).

38. J.F. Wright. Gene Ther. 15 (11), 840–848 (2008).

39. R. Prylman, L. Schuerman. Expert Rev. Vaccines. 8 (11), 1479-1500 (2009).

40. T. Vesikari, et.al., The Pediatr. Infect. Dis. J. 28 (4), S66–S76 (2009).

41. FDA, Guidance for Industry: Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies (Rockville, MD, April 1997).

42. G.T. Jennings and M.F. Bachmann, Annu. Rev. Pharmacol. Toxicol. 49, 303–326 (2009).

43. B. Keshab et. al., presentation at AIChE Annual Meeting (Salt Lake City, UT, 2009).

44. W. Waterfield, presentation at BioProcess International Conference & Exhibition (Providence, RI, 2010)

45. E. Shacter, presentation at American Chemical Society Conference (San Franscisco, 2010).

46. EMA CMHP, Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues (London, England, Feb. 2006).

47. C.K. Schneider and U. Kalinke, Nat. Biotechnol. 26 (9), 985-990 (2008).

48. G. Saberwal, Current Sci. 98 (12), 1575–1578 (2010).

49. R.L. Fahrner et. al., Biotechnol. Genet. Eng. Rev. 18, 301-327 (2001).

50. ISPE, "A-Mab: A Case Study in Bioprocess Development" 2009, http://www.ispe.org/PQLI_A_Mab_Case_Study_Version_2_1.pdf/, accessed Mar. 1, 2011.

51. P.J. Declerck et. al., Curr. Med. Res. Opin. 26 (5), 1219-1229 (2010).

52. S. Kozlowski, P. Swann. "Considerations for Biotechnology Product Quality by Design." In Quality by Design for Biopharmaceuticals: Principles and Case Studies, A.S. Rathore and R Mhatre eds. (John Wiley & Sons, Inc., Hoboken, New Jersey, 2009) pp 9-27.

53. FDA, Notice of pilot program (Rockville MD, July 2008)

54. ICH, Q8(R2) Pharmaceutical Development (Geneva, August 2009).

55. ICH, Q10 Pharmaceutical Quality System (Geneva, May 2007).

56. ICH, Q9 Quality Risk Management (Geneva, November 2005).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here